While drug development is still at the forefront for GlaxoSmithKline, the pharma giant has been quietly working on electroceuticals since 2012. It aims to bring a product to market within the next decade.
Starting this Sunday, the 155 countries that use the trivalent oral polio vaccine will switch over to the bivalent vaccine.
Humira is refusing to go quietly. Even as the anti-inflammatory faces patent expiration in the U.S. later this year, AbbVie continues not only an aggressive advertising push, but also a similarly strong legal and patent effort to keep biosimilar versions off the market.
Quick on the heels of backing from a key European committee, GlaxoSmithKline is gearing up to launch Strimvelis, a breakthrough gene therapy for children. To lay that groundwork, the drugmaker is opening the door to radical changes in payments for the ultrapricey med to keep its cost from breaking the bank.
A battle for kids' pollen proclivities is shaping up this allergy season. Both Sanofi's Nasacort and GlaxoSmithKline's Flonase have introduced children's-labeled versions of the now-OTC steroid nasal sprays for the spring season.
GlaxoSmithKline plans a radical shift in patent policy that seeks to encourage copies of its medicines in poor countries, widening access and possibly diminishing calls for compulsory licenses or other challenges based on price.
A new contract research organization has risen out of the flames of Glaxo's former Canadian vaccines unit as it sets up shop in the pharma company's old Laval facility.
Through its recent purchases and divestitures, GlaxoSmithKline has placed an increased emphasis on its vaccines business worldwide. Now, it'll look to build its vaccine offerings in one of the world's most populous countries, with an executive this week saying the British pharma giant aims to launch in India multiple combination vaccines in the coming months.
GlaxoSmithKline is collaborating with Germany's Miltenyi Biotec on the "industrialization" of cell and gene therapy, as part of the Big Pharma's effort to harness the technique for the development of therapies to treat cancer and rare diseases.
In a twist on the traditional smoking cessation model, GlaxoSmithKline is pairing with 2morrow's SmartQuit app to supply patches to smokers who have already completed the app plan.